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	 2‐Amino‐4‐phenyl‐4,5‐dihydro‐5‐oxopyrano[2,3‐c]chromen‐3‐carbonitrile	 derivatives	 (8a‐d)
have	 been	 isolated	 in	 good	 yields	 by	 the	 reaction	 of	 corresponding	 4‐hydroxycoumarin	 (1)
with	 substituted	 aldehydes	 (2a‐d)	 and	 malononitrile	 (3)	 under	 reflux	 conditions.	 The
reactivity	 of	 α‐functionalized	 iminoethers	 (9a‐d)	 with	 hydrazine,	 hydroxylamine	 and
piperidine	 was	 studied.	 The	 synthesized	 compounds	 were	 characterized	 by	 various
techniques	 including	 spectroscopy.	 Compounds	 8‐11	 were	 also	 evaluated	 as	 potential
acetylcholinesterase	inhibitors.	
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1.	Introduction	
	
4‐Hydroxycoumarins	 (2H‐1‐benzopyran‐2‐ones)	 have	
evoked	a	great	deal	of	interest	due	to	their	biological	properties	
and	 characteristic	 conjugated	molecular	 architecture.	Many	of	
them	 display	 important	 pharmacological	 effects,	 including	
analgesic	 [1],	 anti‐arthritis	 [2],	 anti‐inflammatory	 [3],	 anti‐
pyretic	[4],	anti‐bacterial	[5],	anti‐viral	[6],	and	anti‐cancer	[7]	
properties.	 4‐Hydroxycoumarin	 and	 its	 derivatives	 have	 been	
effectively	 used	 as	 anticoagulants	 for	 the	 treatment	 of	
disorders	 in	 which	 there	 is	 excessive	 or	 undesirable	 clotting,	
such	 as	 thrombophlebitis	 [8],	 pulmonary	 embolism	 [9],	 and	
certain	 cardiac	 conditions	 [10].	 A	 number	 of	 comparative	
pharmacological	 investigations	 of	 the	 4‐hydroxycoumarin	
derivatives	 have	 shown	 good	 anticoagulant	 activity	 combined	
with	low	side	effects	and	little	toxicity	[11].	
Our	 research	 has	 been	 devoted	 to	 the	 development	 of	
several	 heterocyclic	 systems	 derived	 from	 4H‐pyrans	
(chromenes)	 as	 starting	 material	 a	 new	 class	 of	 heterocyclic	
systems	with	the	hope	that	they	may	be	biologically	active.	We	
report	here,	facile	syntheses	approaches	to	several	heterocyclic	
systems	 derived	 from	 4H‐pyrans	 (chromenes)	 as	 starting	
material,	 for	which	we	have	 evaluated	 their	 anti‐acetylcholin‐
esterase	activity.	
2.	Experimental		
	
2.1.	Instrumentation	
	
1H	 NMR	 (300	MHz)	 and	 13C	 NMR	 (75	MHz)	 spectra	were	
recorded	in	deuterated	CDCl3	and	DMSO‐d6	on	a	Bruker	AC‐300	
using	 non‐deuterated	 solvents	 as	 internal	 reference.	 All	
chemical	shifts	were	reported	as	δ	values	(ppm)	and	coupling	
constants	 (J)	 were	 expressed	 in	 Hz.	 All	 reactions	 were	
monitored	by	TLC	using	aluminium	sheets	of	SDS	silica	gel	60	
F254,	0.2	mm.		
	
2.2.	Biological	properties	
	
Acetylcholinesterase	 enzymatic	 activity	 was	 measured	 by	
the	Ellman	test	[12],	98	μL	(50	mM)	Tris‐HCl	buffer	pH	=	8.	30	
μL	sample	and	7.5	μL	acetylcholinesterase	solutions	containing	
0.26	 U/mL	 were	 mixed	 in	 an	 ELISA	 plate	 well	 and	 left	 to	
incubate	 for	 15	 min.	 Subsequently,	 22.5	 μL	 of	 AtchI	 (Acetyl	
thiocholine	 iodide,	 substrate	 concentration	 =	 0.023	 mg/mL)	
and	 142	 μL	 of	 DTNB	 (5,5‐Dithio‐bis(2‐nitrobenzoic	 acid),	
chromogen	concentration	=	3	mM)	were	added.		
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Scheme	1	
	
	
The	 absorbance	 at	 405	 nm	 was	 read	 when	 there	 action	
reached	the	equilibrium.	A	control	action	was	carried	out	using	
water	instead	of	compound.		
The	 absorbance	 value	 obtained	 was	 considered	 100%	
activity.	Inhibition	(%)	was	calculated	with	Equation	(1).	
	
I	%	=	100‐(Asample/Acontrol)	×	100	 	 	 (1)	
	
where,	Asample	 is	 the	absorbance	of	 the	reaction	containing	 the	
extract	and	Acontrol	the	absorbance	of	the	reaction	control.	Tests	
were	carried	out	 in	 triplicate	and	a	blank	with	Tris‐HCl	buffer	
instead	 of	 enzyme	 solution	 was	 done.	 Sample	 concentration	
providing	 50%	 inhibition	 (IC50)	 was	 obtained	 plotting	 the	
inhibition	 percentage	 against	 compound	 solution	 concentra‐
tions.	
	
2.3.	Synthesis	
	
Starting	materials	were	prepared	using	 standard	methods	
[13,14].	
	
2.3.1.	Reaction	of	4‐hydroxycoumarin	(1)	with	compounds	
2a‐d	
	
General	 procedure:	 To	 a	 stirred	 mixture	 of	 4‐hydroxy	
coumarin	 (1)	 (3	mmol)	 and	benzaldyde	 (2a‐d)	 (3	mmol)	 and	
malononitrile	 (3)	 (3	 mmol)	 in	 absolute	 ethanol	 (30	mL)	 was	
added	 anhydrous	 sodium	 carbonate	 (32.68	 mg,	 0.308	mmol)	
and	 the	 mixture	 was	 heated	 under	 reflux.	 A	 TLC	 control	
showed	 that	 the	 reaction	was	 completed	 after	 an	 hour.	 After	
cooling,	 the	 mixture	 diluted	 with	 cold	 ethanol	 when	 a	 solid	
formed	which	collected	by	filtration,	washed	several	times	with	
cold	ethanol	and	dried	and	recrystallized	from	ethanol	to	afford	
the	chromenes	8a‐d	(Scheme	1).	
2‐Amino‐5‐oxo‐4‐phenyl‐4,5‐dihydropyrano[3,2‐c]chromene‐
3‐carbonitrile	 (8a):	 Color:	 White.	 Yield:	 80%.	 1H	 NMR	 (300	
MHz,	DMSO‐d6,	δ,	ppm):	4.45	(s,	1H,	CH‐Ph),	7.28‐7.38	(m,	5H,	
NH2,	Ar‐H),	7.47‐7.53	(m,	4H,	Ar‐H),	7.79	(t,	1H,	J	=	8.1	Hz,	Ar‐
H),	7.90	(d,	1H,	J	=	7.8	Hz,	Ar‐H).	13C	NMR	(75	MHz,	DMSO‐d6,	δ,	
ppm):	159.9	(1C,	CO),	158.3	(1C,	Ar‐C),	153.7	(1C,	Ar‐C),	152.5	
(1C,	Ar‐C),	143.7	(1C,	Ar‐C),	133.3	(1C,	Ar‐C),	128.8	(2C,	Ar‐C),	
127.9	(2C,	Ar‐C),	127.4	(1C,	Ar‐C),	125.0	(1C,	Ar‐C),	122.8	(1C,	
Ar‐C),	119.6	(1C,	Ar‐C),	116.9	(1C,	Ar‐C),	113.3	(1C,	CN),	104.3	
(1C,	 Ar‐C),	 58.2	 (1C,	 Ar‐C),	 37.3	 (1C,	 CH‐Ph).	 Anal.	 calcd.	 for	
C19H12N2O3:	C,	72.15;	H,	3.82;	N,	8.86.	Found:	C,	72.20;	H,	3.85;	
N,	8.90%.	
2‐Amino‐4‐(4‐chlorophenyl)‐5‐oxo‐4,5‐dihydropyrano[3,2‐c]	
chromene‐3‐carbonitrile	(8b):	Color:	White.	Yield:	75%.	1H	NMR	
(300	MHz,	DMSO‐d6,	δ,	ppm):	4.72	(s,	1H,	CH‐Ph),	7.40‐8.13	(m,	
10H,	 NH2,	 Ar‐H).	 13C	 NMR	 (75	MHz,	DMSO‐d6,	 δ,	 ppm):	 160.4	
(1C,	CO),	158.9	(1C,	Ar‐C),	154.4	(1C,	C‐NH2),	153.2	(1C,	Ar‐C),	
143.1	 (1C,	Ar‐C),	133.8	 (1C,	C‐Cl),	130.6	 (2C,	Ar‐C),	128.8	 (2C,	
Ar‐C),	127.9	(1C,	Ar‐C),	127.4	(1C,	Ar‐C),	125.0	(1C,	Ar‐C),	122.8	
(1C,	 Ar‐C),	 119.6	 (1C,	 Ar‐C),	 113.3	 (1C,	 CN),	 104.4	 (1C,	 Ar‐C),	
58.6	(1C,	Ar‐C),	38.3	(1C,	CH‐Ph).	
2‐Amino‐5‐oxo‐4‐(p‐tolyl)‐4,5‐dihydropyrano[3,2‐c]chrome	
ne‐3‐carbonitrile	 (8c):	Color:	White.	Yield:	80%.	 1H	NMR	 (300	
MHz,	DMSO‐d6,	 δ,	 ppm):	 2.25	 (s,	 3H,	 CH3),	 4.40	 (s	 1H,	 CH‐Ph‐
CH3),	7.12‐7.93	(m,	10H,	NH2,	Ar‐H).	13C	NMR	(75	MHz,	DMSO‐
d6,	δ,	ppm):	159.8	(1C,	CO),	158.4	(1C,	Ar‐C),	153.7	(1C,	C‐NH2),	
152.5	(1C,	Ar‐C),	140.8	(1C,	Ar‐C),	136.7	(1C,	Ar‐C),	133.2	(1C,	
Ar‐C),	129.5	(2C,	Ar‐C),	128.9	(2C.	Ar‐C),	127.9	(1C,	Ar‐C),	122.8	
(1C,	 Ar‐C),	 119.7	 (1C,	 Ar‐C),	 116.9	 (1C,	 Ar‐C),	 113.4	 (1C,	 CN),	
104.6	(1C,	Ar‐C),	58.6	(1C,	Ar‐C),	37.0	(1C,	CH‐Ph‐Me),	21.0	(1C,	
CH3).	 Anal.	 calcd.	 for	 C20H14N2O3:	 C,	 72.12;	 H,	 4.27;	 N,	 8.48.	
Found:	C,	72.16;	H,	4.30;	N,	8.50%.	
2‐Amino‐5‐oxo‐4‐(4‐methoxyphenyl)‐4,5‐dihydropyrano[3,2‐
c]chromene‐3‐carbonitrile	 (8d):	 Color:	 White.	 Yield:	 85%.	 1H	
NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	3.71	(s,	3H,	CH3O),	4.39	(s,	
1H,	CH),	6.80‐7.85	(m,	10H,	NH2,	Ar‐H).		
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13C	NMR	(75	MHz,	DMSO‐d6,	δ,	ppm):	161.2	(1C,	CO),	158.8	
(1C,	Ar‐C),	158.5	(1C,	C‐NH2),	154.5	(1C,	C‐O‐Me),	151.7	(1C,	Ar‐
C),	 135.9	 (1C,	 Ar‐C),	 133.1	 (2C,	 Ar‐C),	 129.0	 (1C,	 Ar‐C),	 125.1	
(1C,	Ar‐C),	121.4	(1C,	Ar‐C),	119.8	(1C,	Ar‐C),	117.2	(1C,	Ar‐C),	
115.0	(2C,	Ar‐C),	111.7	(1C,	CN),	106.4	(1C,	Ar‐C),	59.1	(1C,	Ar‐
C),	56.1	(1C,	CH3‐O),	36.7	(1C,	CH‐Ph‐Me).		
	
2.3.2.	Reaction	of	compounds	8a‐d	with	triethylortho	
formate	
	
General	 procedure:	 A	 mixture	 of	 compounds	 8a‐d	 (0.01	
mmol),	 triethylorthoformate	 (0.01	 mmol)	 and	 Ac2O	 (30	 mL)	
was	refluxed	for	6	h.	The	solid	product	that	precipitated	during	
the	reflux	was	filtered	off,	dried	and	recrystallized	from	ethanol	
to	give	compounds	9a‐d	(Scheme	2).	
Ethyl‐N‐(3‐cyano‐5‐oxo‐4‐phenyl‐4,5‐dihydropyrano[3,2‐c]	
chromen‐2‐yl)formimidate	(9a):	Color:	White	solid.	Yield:	80%.	
1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	1.34	(t,	3H,	J	=	9	Hz,	CH3‐
CH2‐O),	4.38	 (q,	2H,	 J	 =	9	Hz,	CH3‐CH2‐O),	4.76	 (s,	1H,	CH‐Ph),	
7.27‐8.22	(m,	9H,	Ar‐H),	8.92	(s,	1H,	N=CH).	13C	NMR	(75	MHz,	
DMSO‐d6,	 δ,	 ppm):	 162.4	 (1C,	 C‐N=CH),	 159.4	 (1C,	 CO),	 158.6	
(1C,	Ar‐C),	155.0	(1C,	‐N=CH‐O),	153.4	(1C,	Ar‐C),	152.1	(1C,	Ar‐
C),	 133.5	 (2C,	 Ar‐C),	 133.0	 (1C,	 Ar‐C),	 132.0	 (1C,	 Ar‐C),	 129.3	
(2C,	Ar‐C),	124.6	(1C,	Ar‐C),	123.4	(1C,	Ar‐C),	116.8	(1C,	Ar‐C),	
116.3	(1C,	Ar‐C),	113.9	(1C,	CN),	103.1	(1C,	Ar‐C),	82.9	(1C,	Ar‐
C),	64.1	(1C,	‐O‐CH2‐CH3),	37.5	(1C,	CH‐Ph),	13.8	(1C,	CH3‐CH2‐
O).	
Ethyl‐N‐(4‐(4‐chlorophenyl)‐3‐cyano‐5‐oxo‐4,5‐dihydropyra	
no[3,2‐c]chromen‐2‐yl)formimidate	 (9b):	 Color:	 White.	 Yield:	
75%.	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	1.35	(t,	3H,	J	=	9	Hz,	
CH3‐CH2‐O),	4.39	(q,	2H,	 J	=	9	Hz,	CH3‐CH2‐O),	4.76	(s,	1H,	CH‐
Ph),	7.42‐8.22	(m,	8H,	Ar‐H),	8.93	(s,	1H,	N=CH).	 13C	NMR	(75	
MHz,	DMSO‐d6,	δ,	ppm):	162.7	(1C,	Ar‐C),	159.4	(1C,	CO),	155.0	
(1C,	O‐CH=N),	153.9	(1C,	Ar‐C),	152.2	(1C,	Ar‐C),	140.5	(1C,	Ar‐
C),	 133.2	 (1C,	 Ar‐C),	 132.3	 (1C,	 Ar‐C),	 130.2	 (2C,	 Ar‐C),	 128.6	
(2C,	Ar‐C),	124.7	(1c,	Ar‐C),	123.6	(1C,	Ar‐C),	116.6	(1C,	Ar‐C),	
116.4	(1C,	Ar‐C),	112.8	(1C,	CN),	102.5	(1C,	Ar‐C),	82.2	(1C,	Ar‐
C),	 64.2	 (1C,	O‐CH2‐CH3),	37.7	 (1C,	CH‐Ph),	13.8	 (1C,	CH3‐CH2‐
O).		
Ethyl‐N‐(3‐cyano‐5‐oxo‐4‐(p‐tolyl)‐4,	 5‐dihydropyrano	 [3,2‐
c]chromen‐2‐yl)formimidate	 (9c):	 Color:	White.	 Yield:	 70%.	 1H	
NMR	 (300	MHz,	DMSO‐d6,	 δ,	 ppm):	1.35	 (t,	 3H,	 J	=	9	Hz,	 CH3‐
CH2‐O),	3.32	(s,	3H,	CH3),	4.38	(q,	2H,	J	=	9	Hz,	O‐CH2‐CH3),	4.65	
(s,	 1H,	 CH‐Ph),	7.18‐8.20	 (m,	8H,	Ar‐H),	8.92	 (s,	 1H,	N=CH‐O).	
13C	NMR	 (75	MHz,	DMSO‐d6,	 δ,	 ppm):	 162.4	 (1C,	 Ar‐C),	 159.4	
(1C,	CO),	155.2	(1C,	O‐CH=N),	153.6	(1C,	Ar‐C),	152.1	(1C,	Ar‐C),	
138.6	(1C,	Ar‐C),	136.9	(1C,	Ar‐C),	133.0	(1C,	Ar‐C),	129.2	(2C,	
Ar‐C),	128.0	(2C,	Ar‐C),	124.7	(1c,	Ar‐C),	123.5	(1C,	Ar‐C),	116.7	
(1C,	 Ar‐C),	 116.4	 (1C,	 Ar‐C),	 112.9	 (1C,	 CN),	 103.0	 (1C,	 Ar‐C),	
82.8	 (1C,	 Ar‐C),	 64.2	 (1C,	 O‐CH2‐CH3),	 37.9	 (1C,	 CH‐Ph),	 20.6	
(1C,	CH3),	13.8	(1C,	CH3‐CH2‐O).		
Ethyl‐N‐(3‐cyano‐4‐(4‐methoxyphenyl)‐5‐oxo‐4,5‐dihydro	
pyrano[3,2‐c]chromen‐2‐yl)formimidate	 (9d):	 Color:	 White.	
Yield:	78	%.	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	1.35	(t,	3H,	J	
=	9	Hz,	CH3‐CH2‐O),	3.33	(s,	3H,	OCH3),	4.38	(q,	2H,	J	=	9	Hz,	O‐
CH2‐CH3),	4.63	(s,	1H,	CH‐Ph),	6.83‐8.21	(m,	8H,	Ar‐H),	8.91	(s,	
1H,	N=CH‐O).	13C	NMR	(75	MHz,	DMSO‐d6,	δ,	ppm):	162.4	(1C,	
Ar‐C),	 159.4	 (1C,	 CO),	 158.7	 (1C,	 O‐CH=N),	 155.1	 (1C,	 Ar‐C),	
153.4	(1C,	Ar‐C),	152.1	(1C,	Ar‐C),	133.6	(1C,	Ar‐C),	133.0	(1C,	
Ar‐C),	129.4	(2C,	Ar‐C),	124.7	(1C,	Ar‐C),	123.5	(1c,	Ar‐C),	116.8	
(1C,	 Ar‐C),	 116.4	 (1C,	 Ar‐C),	 113.9	 (2C,	 Ar‐C),	 112.9	 (1C,	 CN),	
103.2	 (1C,	 Ar‐C),	 82.9	 (1C,	 Ar‐C),	 64.2	 (1C,	 O‐CH2‐CH3),	 55.1	
(1C,	O‐CH3),	37.5	(1C,	CH3),	13.8	(1C,	CH3‐CH2‐O).		
	
2.3.3.	Reaction	of	compound	8a	with	formic	acid	
	
A	mixture	of	the	chromene	8a	(0.01	mmol)	and	formic	acid	
(20	mL)	was	refluxed	 for	5	h.	The	mixture	cooled	 it	as	a	solid	
started	 to	 form	 and	 the	 precipitate	 filtered	 off,	 then	 washed	
with	 water	 and	 diethyl	 ether.	 The	 solid	 recrystallized	 from	
ethanol	 and	 afforded	 the	 4‐phenyl‐3,4‐dihydropyrano[3,2‐c]	
chromene‐2,5‐dione,	10	(Scheme	2).	
4‐Phenyl‐3,4‐dihydropyrano[3,2‐c]chromene‐2,5‐dione	 (10):	
Color:	White.	Yield:	80%.	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	
2.99	(dd,	1H,	J	=	1.2	Hz,	CH2),	3.57	(dd,	1H,	J	=	7.8	Hz,	CH2),	4.45	
(d,	1H,	J	=	7.8	Hz,	CH‐Ph),	7.22‐7.87	(m,	9H,	Ar‐H).	13C	NMR	(75	
MHz,	DMSO‐d6,	δ,	ppm):	165.6	(1C,	O‐CO‐CH2),	160.7	(1C,	O‐CO‐
C),	 157.7	 (1C,	 Ar‐C),	 153.1	 (1C,	 Ar‐C),	 140.5	 (1C,	 Ar‐C),	 133.6	
(1C,	Ar‐C),	129.6	(1C,	Ar‐C),	128.0	(2C,	Ar‐C),	127.1	(2C,	Ar‐C),	
125.4	(1C,	Ar‐C),	123.0	(1C,	Ar‐C),	117.2	(1C,	Ar‐C),	113.8	(1C,	
Ar‐C),	106.6	(1C,	Ar‐C),	36.7	(1C,	CH‐Ph),	35.8	(1C,	CH2).		
	
2.3.4.	Reaction	of	compounds	9a‐d	with	hydrazine	hydrate	
	
General	 procedure:	 A	 solution	 of	 compounds	 9a‐d	 (0.01	
mmol)	 and	 hydrazine	 hydrate	 (5	 mL)	 in	 EtOH	 (50	 mL)	 was	
sttired	 at	 room	 temperature	 for	 1	 h.	 The	 solid	 product	 was	
collected	 by	 filtration	 and	 recrystallized	 from	 ethanol	 to	 give	
compounds	11a‐d	(Scheme	3).	
9‐Amino‐8‐imino‐7‐phenyl‐8,9‐dihydrochromeno[3’,4’,5,6]	
pyrano[2,3‐d]pyrimidin‐6(7H)‐one	 (11a):	 Color:	 White.	 Yield:	
72%.	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	4.99	(s,	1H,	CH‐Ph),	
5.73	 (s,	 2H,	 NH2),	 7.14‐7.94	 (m,	 10H,	 NH,	 Ar‐H),	 8.17	 (s,	 1H,	
CH=N).	 13C	NMR	 (75	MHz,	 DMSO‐d6,	 δ,	 ppm):	 163.1	 (1C,	 CO),	
161.0	(1C,	Ar‐C),	160.3	(1C,	Ar‐C),	157.2	(1C,	C=NH),	155.0	(1C,	
Ar‐C),	152.5	(1C,	Ar‐C),	142.1	(1C,	N=C‐N‐NH2),	133.3	(1C,	Ar‐
C),	 128.9	 (2C,	 Ar‐C),	 128.7	 (1C,	 Ar‐C),	 127.7	 (2C,	 Ar‐C),	 125.3	
(1C,	Ar‐C),	123.1	 (1C,Ar‐C),	117.0	 (1C,	Ar‐C),	113.9	 (1C,	Ar‐C),	
106.2	(1C,	Ar‐C),	96.6	(1C,	Ar‐C),	34.0	(1C,	CH).	
9‐Amino‐7‐(4‐chlorophenyl)‐8‐imino‐8,9‐dihydrochromeno	
[3’,4’,5,6]pyrano[2,3‐d]pyrimidin‐6(7H)‐one	(11b):	Color:	White.	
Yield:	70%.	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	4.99	(s,	1H,	
CH‐Ph),	5.76	(s,	2H,	NH2),	7.12‐7.93	(m,	9H,	NH,	Ar‐H),	8.17	(s,	
1H,	 CH=N).	 13C	 NMR	 (75	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 164.0	 (1C,	
C=NH),	163.1	(1C,	CH=N),	159.8	(1C,	CO),	154.2	(1C,	Ar‐C),		
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152.0	(1C,	Ar‐C),	151.3	(1C,	Ar‐C),	140.8	(1C,	Ar‐C),	132.8	(1C,	
Ar‐C),	131.6	(1C,	Ar‐C),	130.7	(2C,	Ar‐C),	127.9	(2C,	Ar‐C),	124.8	
(1C,	Ar‐C),	122.5	(1C,	Ar‐C),	116.5	(1C,	Ar‐C),	113.2	(1C,	Ar‐C),	
104.3	(1C,	Ar‐C),	99.6	(1C,	Ar‐C),	34.8	(1C,	CH).	
9‐Amino‐8‐imino‐7(p‐tolyl)‐8,9‐dihydrochromeno[3’,4’,5,6]	
pyrano[2,3‐d]pyrimidin‐6(7H)‐one	 (11c):	 Color:	 White.	 Yield:	
78%.	 1H	NMR	 (300	MHz,	DMSO‐d6,	 δ,	ppm):	2.50	 (s,	3H,	CH3),	
4.97	(s,	1H,	CH‐Ph),	5.77	(s,	2H,	NH2),	7.15‐7.91	(m,	9H,	NH,	Ar‐
H),	 8.16	 (s,	 1H,	 CH=N).	 13C	NMR	 (75	MHz,	 DMSO‐d6,	 δ,	 ppm):	
159.8	 (1C,	 CO),	 154.2	 (1C,	 Ar‐C),	 152.0	 (1C,	 Ar‐C),	 151.3	 (1C,	
C=NH),	 148.4	 (1C,	 Ar‐C),	 147.2	 (1C,	 Ar‐C),	 140.9	 (1C,	 CH=N),	
132.8	(1C,	Ar‐C),	131.6	(1C,	Ar‐C),	130.7	(2C,	Ar‐C),	127.9	(2C,	
Ar‐C),	124.7	(1C,	Ar‐C),	122.5	(1C,	Ar‐C),	116.5	(1C,	Ar‐C),	113.1	
(1C,	Ar‐C),	104.3	(1C,	Ar‐C),	99.8	(1C,	Ar‐C),	54.9	(1C,	CH),	34.8	
(1C,	CH3).	
9‐Amino‐8‐imino‐7(4‐methoxyphenyl)‐8,9‐dihydrochromeno	
[3’,4’,5,6]pyrano[2,3‐d]pyrimidin‐6(7H)‐one	(11d):	Color:	White.	
Yield:	78%.	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	2.50	(s,	3H,	
OCH3),	4.90	(s,	1H,	CH‐Ph),	5.76	(s,	2H,	NH2),	6.79‐7.92	(m,	9H,	
NH,	Ar‐H),	8.15	 (s,	1H,	CH=N).	 13C	NMR	(75	MHz,	DMSO‐d6,	 δ,	
ppm):	159.8	(1C,	CO),	158.2	(1C,	Ar‐C),	154.0	(1C,	Ar‐C),	153.8	
(1C,	C=NH),	151.9	(1C,	C‐OCH3),	150.8	(1C,	Ar‐C),	148.0	(1C,	Ar‐
C),	 146.8	 (1C,	 Ar‐C),	 133.9	 (1C,	 Ar‐C),	 132.6	 (1C,	 Ar‐C),	 129.8	
(2C,	Ar‐C),	124.7	(1C,	Ar‐C),	122.4	(1C,	Ar‐C),	116.5	(1C,	Ar‐C),	
113.5	 (2C,	 Ar‐C),	 113.2	 (1C,	 Ar‐C),	 104.9	 (1C,	 Ar‐C),	 54.9	 (1C,	
OCH3),	34.8	(1C,	CH).	
	
2.3.5.	Reaction	of	compounds	9a‐d	with	hydroxylamine	
	
General	 procedure:	 A	 mixture	 of	 compounds	 9a‐d	 (0.01	
mmol)	and	hydroxylamine	(10	mL)	in	methanol:THF	(v:v,	14:6)	
(20	 mL)	 was	 stirred	 at	 room	 temperature	 for	 1	 h.	 The	 solid	
product	was	 collected	 and	 recrystallized	 from	 ethanol	 to	 give	
compounds	12a‐d	(Scheme	3).		
N‐(3‐Cyano‐5‐oxo‐4‐phenyl‐4,5‐dihydropyrano[3,2‐c]chro	
men‐2‐yl)formimidamide	 (12a):	 Color:	 White.	 Yield:	 85%.	 1H	
NMR	 (300	MHz,	 DMSO‐d6,	 δ,	 ppm):	 4.55	 (s,	 1H,	 CH‐Ph),	 7.26‐
8.06	(m,	10H,	NH,	Ar‐H),	8.44	(d,	1H,	J	=	13.8	Hz,	‐NH),	8.56	(dd,	
1H,	 J	 =	9.6	Hz,	CH=NH).	 13C	NMR	(75	MHz,	DMSO‐d6,	 δ,	ppm):	
160.0	 (1C,	 CO),	 158.4	 (1C,	 Ar‐C),	 156.0	 (1C,	 Ar‐C),	 154.2	 (1C,	
C=NH),	152.5	 (1C,	C‐OCH3),	143.0	 (1C,	Ar‐C),	133.2	 (1C,	Ar‐C),	
128.9	 (2C,	Ar‐C),	 128.3	 (1C,	Ar‐C),	 127.6	 (2C,	Ar‐C),	 125.0(1C,	
Ar‐C),	123.3	(1C,	Ar‐C),	119.3	(1C,	Ar‐C),	116.8	(1C,	Ar‐C),	113.6	
(1C,	CN),	103.7	(1C,	Ar‐C),	74.4	(1C,	Ar‐C),	34.8	(1C,	CH).	
N‐(4‐(4‐Chlorophenyl)‐3‐cyano‐5‐oxo‐4,5‐dihydropyrano	 [3,	
2‐c]chromen‐2‐yl)formimidamide	 (12b):	 Color:	 White.	 Yield:	
85%.	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	4.55	(s,	1H,	CH‐Ph),	
7.25‐8.04	(m,	9H,	NH,	Ar‐H),	8.44	(d,	1H,	J	=	13.8	Hz,	‐NH),	8.56	
(dd,	 1H,	 J	 =	 9.6	 Hz,	 CH=NH).	 13C	 NMR	 (75	 MHz,	 DMSO‐d6,	 δ,	
ppm):	162.6	(1C,	CO),	160.5	(1C,	Ar‐C),	159.8	(1C,	Ar‐C),	156.8	
(1C,	C=NH),	154.6	(1C,	C‐OCH3),	152.1	(1C,	Ar‐C),	140.5	(1C,	Ar‐
C),	 132.9	 (1C,	 Ar‐C),	 131.8	 (1C,	 C‐Cl),	 130.3	 (2C,	 Ar‐C),	 128.1	
(2C,	Ar‐C),	124.8	(1C,	Ar‐C),	122.6	(1C,	Ar‐C),	116.5	(1C,	Ar‐C),	
113.3	(1C,	CN),	105.2	(1C,	Ar‐C),	95.6	(1C,	Ar‐C),	33.0	(1C,	CH).	
N‐(3‐Cyano‐5‐oxo‐4‐(p‐totyl)‐4,5‐dihydropyrano[3,2‐c]chro	
men‐2‐yl)formimidamide	 (12c):	 Color:	 White.	 Yield:	 80%.	 1H	
NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	2.50	(s,	3H,	CH3),	5.1	(s,	1H,	
CH‐Ph),	7.25‐8.04	(m,	9H,	NH,	Ar‐H),	8.44	(d,	1H,	J	=	13.8	Hz,	‐
NH),	8.56	(dd,	1H,	J	=	9.6	Hz,	CH=NH).	13C	NMR	(75	MHz,	DMSO‐
d6,	δ,	ppm):	162.5	 (1C,	CO),	160.4	(1C,	Ar‐C),	159.7	(1C,	Ar‐C),	
156.6	 (1C,	C=NH),	154.3	 (1C,	C‐OCH3),	152.0	 (1C,	Ar‐C),	138.6	
(1C,	Ar‐C),	136.3	(1C,	Ar‐C),	132.7	(1C,	Ar‐C),	128.8	(2C,	Ar‐C),	
128.2	(2C,	Ar‐C),	124.8	(1C,	Ar‐C),	122.5	(1C,	Ar‐C),	116.5	(1C,	
Ar‐C),	 113.3	 (1C,	 CN),	 105.7	 (1C,	 Ar‐C),	 96.1	 (1C,	 Ar‐C),	 33.1	
(1C,	CH),	20.5(1C,	CH3).	
N‐(3‐Cyano‐4‐(4‐methoxyphenyl)‐5‐oxo‐4,5‐dihydropyrano	
[3,2‐c]chromen‐2‐yl)formimidamide	 (12d):	 Color:	White.	 Yield:	
85%.	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	3.80	(s,	3H,	OCH3),	
4.80	(s,	1H,	CH‐Ph),	7.34‐8.02	(m,	9H,	NH,	Ar‐H),	8.40	(d,	1H,	J	=	
13.8	Hz,	 ‐NH),	8.50	 (dd,	1H,	 J	 =	9.6	Hz,	CH=NH).	 13C	NMR	 (75	
MHz,	DMSO‐d6,	δ,	ppm):	160.5	(1C,	CO),	159.4	(1C,	Ar‐C),	158.7	
(1C,	Ar‐C),	155.6	(1C,	C=NH),	153.2	(1C,	C‐OCH3),	151.5	(1C,	Ar‐
C),	 138.5	 (1C,	 Ar‐C),	 136.6	 (1C,	 Ar‐C),	 130.7	 (2C,	 Ar‐C),	 128.3	
(1C,	Ar‐C),	125.0	(1C,	Ar‐C),	123.7	(1C,	Ar‐C),	115.1	(1C,	Ar‐C),	
116.0	(1C,	Ar‐C),	113.9	(2C,	Ar‐C),	113.2	(1C,	CN),	104.7	(1C,	Ar‐
C),	96.1	(1C,	Ar‐C),	38.7(1C,	CH).	
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2.3.6.	Reaction	of	compound	9a	with	piperidine	
	
Compound	9a	(1	mmol),	piperidine	(3	mL)	and	toluene	(20	
mL)	 was	 refluxed	 for	 3	 h.	 The	 solvent	 was	 removed	 under	
reduced	 pressure	 and	 the	 resulting	 solid	 was	 recrystallized	
from	ethanol:petrol	ether	(v:v,	14:6)	(20	mL)	to	give	compound	
13a	(Scheme	3).	
5‐Oxo‐4‐phenyl‐2‐((piperidin‐1‐ylmethylene)amino)‐4,5‐di	
hydropyrano[3,2‐c]chromene‐3‐carbonitrile	(13a):	Color:	White.		
Yield:	80%.	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	1.56‐1.64	(m,	
6H,	 CH2‐CH2‐CH2),	 3.65‐3.71	 (m,	 4H,	 CH2‐N‐CH2),	 4.55	 (s,	 1H,	
CH‐Ph),	7.22‐8.32	(m,	9H,	Ar‐H),	8.57	(s,	1H,	N=CH‐N).	13C	NMR	
(75	MHz,	DMSO‐d6,	 δ,	 ppm):	 160.1	 (1C,	 Ar‐C),	 157.7	 (1C,	 CO),	
154.3	(1C,	Ar‐C),	153.2	(1C,	Ar‐C),	152.5	(1C,	Ar‐C),	143.1	(1C,	
Ar‐C),	133.2	(1C,	Ar‐C),	128.9	(2C,	Ar‐C),	128.2	(1C,	Ar‐C),	127.6	
(2C,	Ar‐C),	124.9	(1C,	Ar‐C),	123.9	(1C,	Ar‐C),	119.5	(1C,	Ar‐C),	
116,7	 (1C,	 Ar‐C),	 113,6	 (1C,	 Ar‐C),	 103,7	 (1C,	 Ar‐C),	 74,1	 (1C,	
Ar‐C),	50.8	(1C,	CH2),	43.3	(1C,	CH2),	38.7	(1C,	Ar‐C),	26.5	(1C,	
CH2),	25.1	(1C,	CH2),	24.0	(1C,	CH2).	
	
3.	Results	and	discussion	
	
3.1.	Synthesis	
	
Treatment	 of	 4‐hydroxycoumarin	 (1)	with	 aryl	 aldehydes	
(2a‐d)	 and	 malononitrile	 (3)	 in	 the	 boiling	 ethanol	 during	
several	hours	in	the	presence	of	anhydrous	sodium	bicarbonate	
as	 a	 catalyst	 gave	 2‐amino‐5‐oxo‐4‐phenyl‐4,5‐
dihydropyrano[3,2‐c]chromene‐3‐carbonitrile	derivatives		(8a‐
d)	in	high	yields	(75‐85%)	(Scheme	1).	
The	1H	NMR	spectra	of	compound	8a	displays	a	signal	at	δ	
4.45	 ppm	 that	 ascribable	 to	 the	 proton	 H4.	 In	 addition,	 the	
aromatic	 protons	 are	 observed	between	δ	7.28	and	7.90	ppm	
(see	experimental),	and	the	expected	singlet	 for	the	proton	H8	
is	observed	at	δ	7.79	ppm	(Scheme	1).	
The	 observed	 high	 regioselectivity	 is	 most	 probably	
associated	 with	 the	 reaction	 sequence	 outlined	 in	 Scheme	 1.	
Initial	Knoevenagal	reaction	between	aldehydes	substitutes	2a‐
d	and	malonitrile	(3)	produces	the	unsaturated	nitrile	4,	which,	
undergoes	a	Michael	 reaction	with	 the	base	derived	coumarin	
anion,	5.	The	resulting	Michael	adduct	6	 then	undergoes	 intra	
molecular	 cyclization	 producing	 the	 annelatediminopyran	 7.	
Subsequent	tautomeric[1,3]	sigmatropic	shift	gives	compounds	
8a‐d.	
Under	 these	 conditions,	 the	 reaction	 proceeds	 sufficiently	
rapidly	 and	 smoothly	 to	 afford	 the	 target	 chromenes	8a‐d	 in	
high	yields	without	Michael	adducts	6	being	detected.	However,	
the	 proposed	 mechanism	 is	 supported	 to	 some	 degree	 by	
isolation	 of	 analogous	 Michael	 adducts	 in	 the	 previously	
studied	 reaction	 of	 4‐hydroxycoumarin	 with	 arylidenecyano	
acetamides	[3].	
Refluxing	 compounds	 8a‐d	 with	 triethylorthoformate	 in	
acetic	anhydride	at	reflux	afforded	the	corresponding	ethyl‐N‐
(3‐cyano‐5‐oxo‐phenyl‐4,5‐dihydropyrano[3,2‐c]chromen‐
2‐yl)formimidate		(9a‐d)	while	with	formic	acid,	chromene‐2,5‐
one‐2,5‐dione	(10)	were	formed,	Scheme	2.		
Hydrazinolysis	 of	 compound	 9a‐d	 in	 ethanol	 at	 room	
temperature	 afforded	 the	 9‐amino‐8‐imino‐7‐phenyl‐8,9‐di	
hydrochromeno	 [3’,4’,5,6]pyrano[2,3‐d]pyrimidin‐6(7H)‐one	
derivatives,	11a‐d.		
Reaction	of	compounds	9a‐d	with	hydroxylamine	in	MeOH‐
THF	 at	 room	 temperature	 yielded	 the	 N‐(3‐cyano‐5‐oxo‐4‐
phenyl‐4,5‐dihydropyrano[3,2‐c]chromen‐2‐
yl)formimidamide	 deriva‐tives,	 12a‐d.	 Interaction	 of	
compounds	 9a‐d	 with	 piperidine	 in	 toluene	 afforded	 the	
chromen	 5‐oxo‐4‐phenyl‐2‐((piperidin‐1‐ylmethylene)	
amino)‐4,5‐dihydropyrano[3,2‐c]chromene‐3‐carbonitrile,	
13a,	Scheme	3.	
The	 structures	 of	 products	 are	 characterized	 by	 1H	 NMR	
along	 with	 13C	 NMR	 are	 in	 agreement	 with	 the	 proposed	
structures.	
	
3.2.	Biological	properties	(Acetylcholinesterase	inhibition)	
	
Inhibition	 of	 acetylcholinesterase	 (AChE),	 the	 key	 enzyme	
in	 the	 breakdown	 of	 acetylcholine,	 is	 considered	 one	 of	 the	
treatment	 strategies	 against	 several	 neurological	 disorders	
such	 as	 Alzheimer’s	 disease,	 senile	 dementia,	 ataxia,	 and	
myasthenia	 gravis	 [15,16].	 The	 acetylcholinesterase	 (AChE)	
inhibition	was	determined	using	 an	 adaptation	of	 the	method	
described	in	the	 literature	[17].	All	compounds	were	analyzed	
on	what	concerns	their	acetylcholinesterase	 inhibition	activity	
(Table	1).	Values	oscillating	between	0.010	and	0.130	mg/mL	
were	 obtained.	 Compared	 to	 those	 given	 in	 the	 literature	 for	
crude	 pure	 products	 [17],	 we	 can	 say	 that	 the	 synthesized	
compounds	8,	9,	10	and	11	are	considered	good	 inhibitors	of	
acetylcholinesterase.	 The	 greatest	 inhibitory	 activity	 was	
exhibited	by	compound	11a	(Ar	=	Ph)	(IC50	=	0.110	μg/mL).	It	
has	been	shown	that	 the	activity	of	 these	derivatives	depends	
in	 general	 on	 the	 nature	 of	 Ar.	 In	 compound	 10,	 the	
acetylcholinesterase	inhibition	decreases	from	Ar	=	Ph	(9a)	to	
Ar	=	p‐MeOPh	(9d).		
The	same	phenomena	have	been	observed	with	compounds	
9a‐d	 and	 8a‐d.	 It	 has	 been	 also	 shown	 that	 the	 activity	
decreases	considerably	when	Ar	varied	in	the	order	Ph,	p‐ClPh,	
p‐MePh	 and	 p‐MeOPh.	 The	 substitution	 of	 both	 the	 phenyl	
seems	to	affect	the	activity	of	the	chromene	skeleton.	
	
Table	 1.	 Acetylcholinesterase	 inhibition	 capacity	 represented	 by	 IC50	
(mg/mL)	of	compounds	8,	9,	10	and	11.	
Compound Acetylcholiinesterase	inhibition	
capacity	represented	by	IC50	(mg/mL)	
8a 0.091
8b 0.065
8c 0.064
8d 0.035
9a 0.130
9b 0.048
9c 0.030
9d	 0.021	
10	 0.077	
11a 0.110
11b	 0.033	
11c	 0.025	
11d 0.010
	
4.	Conclusion	
	
In	 conclusion,	 this	 work	 reports	 the	 synthesis	 of	 3,4‐
dihydropyrano[c]chromene	derivatives	and	their	evaluation	as	
acetyl	 cholinesterase	 inhibitors,	 via	 the	 simple	 and	 useful										
4‐hydroxycoumarin	 (1)	with	 substituted	 aldehydes	 2a‐d	 and	
malonitrile	(3)	under	reflux	reaction	conditions.		
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